About Insight Genetics
Insight Genetics is a Healthcare company based in Nashville (United States) founded in 2007, and was acquired by OncoCyte in January 2020. Molecular diagnostics company that is working to enhance the diagnosis, monitoring and treatment of cancer. Insight Genetics has raised $3.05 million across 8 funding rounds from investors including OncoCyte and National Cancer Institute. The company has 3 employees. Insight Genetics offers products and services including DetermaIO, VitaGraft Kidney, VitaGraft Liver, and GraftAssure. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Lung cancer. Its legal entity is Oncocyte Corporation. Its competitors include ChromaCode, Biodesix and OncoCyte; 3 of its 3 listed competitors have raised funding.
Company details
Insight Genetics was founded in 2007 in Nashville, United States, within the molecular diagnostics sector. Precision cancer care is advanced through the discovery, development, and commercialization of companion diagnostics. Cancer testing services are provided to oncologists and pharmaceutical companies. A suite of molecular tests is offered, including the Insight ALK Screen and resistance assays for ALK-associated cancers, along with biomarkers, multiplex testing, next-generation sequencing, non-invasive methods, and resistance monitoring assays.
- Headquarters Nashville, United States
- Employees 3
- Stage Acquired
- SectorsHealthcare
- Website insightgenetics.com
- Social LinkedIn X Facebook
- Acquired by OncoCyte (Jan 2020)
- Legal Name Oncocyte Corporation
Products & Services of Insight Genetics
Insight Genetics offers a comprehensive portfolio of products and services, including DetermaIO, VitaGraft Kidney, VitaGraft Liver, and GraftAssure.
Assay for predicting immune therapy response in oncology.
Test for monitoring kidney transplant graft health.
Test for assessing liver transplant graft status.
Kit for detecting donor-derived cell-free DNA.
Funding Insights of Insight Genetics
Insight Genetics has successfully raised a total of $3.05M across 8 strategic funding rounds. The most recent funding activity was a Series A round of $3.05 million completed in November 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $3.05M
- Total Rounds 8
- Last Round Series A — $3.05M
- First Round $200,000
(Nov 2010)
- Investors Count 1
All 8 funding rounds of Insight Genetics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2015 | $3.05M | Series A | – | – | – |
| Jan 2014 | $1.5M | Grant | – | – | |
| Aug 2013 | $1.5M | Grant | – | – | |
| Nov 2012 | $1.7M | Grant | – | – | |
| Oct 2012 | $1.5M | Grant | – | – | |
| Oct 2011 | $193,000 | Grant | – | – | |
| Nov 2010 | $244,479 | Grant | – | – | – |
| Nov 2010 | $200,000 | Grant | – | – |
2 investors in total: 2 institutional.
Investors in Insight Genetics
Insight Genetics has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include OncoCyte and National Cancer Institute.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Cancer research is conducted and supported by the institute. | cancer.gov | Bethesda, United States | ||
Non-invasive diagnostic test solutions for cancer treatment are developed. | 2009 | oncocyte.com | Irvine, United States |
Investor details for Insight Genetics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Insight Genetics
4 dated milestones of Insight Genetics across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Insight Genetics is founded.
- Funding First funding round of $200K.
- Funding Latest funding round, Series A, of $3.0M.
- Exit Acquired by OncoCyte.
Competitors of Insight Genetics
Insight Genetics has 3 listed competitors in our database, 3 of them funded. They include ChromaCode, Biodesix and OncoCyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| chromacode.com | 2012 | Carlsbad, United States | $95.02M | 46 | Digital molecular biology analytics are developed for disease management. | |
| biodesix.com | 2005 | Boulder, United States | $200.16M | 217 | Cancer detection diagnostics assays are developed and offered. | |
| oncocyte.com | 2009 | Irvine, United States | $15.35M | 76 | Non-invasive diagnostic test solutions for cancer treatment are developed. |
Detailed competitors of Insight Genetics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Insight Genetics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Insight Genetics
Complete news archive for Insight Genetics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Insight Genetics
Insight Genetics was founded in 2007 and raised its 1st funding round 3 years after it was founded.
Insight Genetics is headquartered in Nashville, United States. It is registered at Nashville, Tennessee, United States.
Insight Genetics is a funded company, having raised a total of $3.05M across 8 funding rounds to date. The company's 1st funding round was a Grant of $200K, raised on Nov 2010.
Insight Genetics has 3 employees.
Insight Genetics was founded in 2007 in Nashville, United States, within the molecular diagnostics sector. Precision cancer care is advanced through the discovery, development, and commercialization of companion diagnostics. Cancer testing services are provided to oncologists and pharmaceutical companies. A suite of molecular tests is offered, including the Insight ALK Screen and resistance assays for ALK-associated cancers, along with biomarkers, multiplex testing, next-generation sequencing, non-invasive methods, and resistance monitoring assays.
Insight Genetics's top competitors include ChromaCode, Biodesix and OncoCyte.
Insight Genetics offers DetermaIO, VitaGraft Kidney, VitaGraft Liver, and GraftAssure.
Insight Genetics has 2 investors. Key investors include OncoCyte, and National Cancer Institute.
Insight Genetics operates through Oncocyte Corporation.
Yes. Insight Genetics was acquired by OncoCyte in January 2020.